Viridian Therapeutics Inc VRDN

Viridian Therapeutics, Inc. is a biotechnology company that develops treatments for serious diseases, including thyroid eye disease and rare diseases that are underserved by current therapies. Founded in 2006, Viridian Therapeutics has its headquarters in Boulder, Colorado.

Previously known as Miragen Therapeutics, Inc., the company changed its name in January 2021 to Viridian Therapeutics, Inc. The most advanced program that Viridian has underway is VRDN-001, which is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody developed to treat thyroid eye disease, a debilitating auto-immune disease with poor treatment options. The company also has a VRDN-002 program focused on the development of a biosuperior IGF-1R antibody. VRDN-002 is a second-generation product candidate designed for subcutaneous administration. Additionally, Viridian Therapeutics has VRDN-004 and VRDN-005 programs in the pipeline.

Available on the NASDAQ, Viridian Therapeutics, Inc. stock is listed under the ticker VRDN. The company's IPO raised approximately $97.7m before expenses in September 2021. Viridian has stated that it intends to use the proceeds to advance the development of VRDN-001 and VRDN-002, in addition to funding preclinical development of its VRDN-004 and VRDN-005 programs and for general corporate purposes and working capital.

Keep an eye on the price movements of VRDN stock by adding it to your eToro watchlist.